Hansa Biopharma Unveils Third Quarter Financial Results for 2025 Hansa Biopharma announces its financial report for Q3 2025, showcasing significant milestones in kidney transplantation and promising growth in product sales.

Hansa Biopharma Unveils Third Quarter Financial Results for 2025 #Sweden #Lund #Hansa_Biopharma #imlifidase #ConfIdeS_Trial

Imlifidase Shows Promising Results in Critical Phase 3 Kidney Transplant Trial Hansa Biopharma's imlifidase meets primary endpoint in US Phase 3 ConfIdeS trial, benefitting kidney transplantation for highly sensitized patients.

Imlifidase Shows Promising Results in Critical Phase 3 Kidney Transplant Trial #USA #Lund #Hansa_Biopharma #imlifidase #ConfIdeS_Trial